Jeroen Otte1, Jaap J van Netten2, Arend-Jan J Woittiez1. 1. Department of Nephrology, Ziekenhuisgroep Twente, Almelo and Hengelo, The Netherlands. 2. Department of Surgery, Ziekenhuisgroep Twente, Almelo and Hengelo, The Netherlands. Electronic address: jv.netten@zgt.nl.
Abstract
OBJECTIVE: The objective of this study was to investigate the risk of chronic kidney disease (CKD) stage 4-5 and dialysis treatment on incidence of foot ulceration and major lower extremity amputation in comparison to CKD stage 3. METHODS: In this retrospective study, all individuals who visited our hospital between 2006 and 2012 because of CKD stages 3 to 5 or dialysis treatment were included. Medical records were reviewed for incidence of foot ulceration and major amputation. The time from CKD 3, CKD 4-5, and dialysis treatment until first foot ulceration and first major lower extremity amputation was calculated and analyzed by Kaplan-Meier curves and multivariate Cox proportional hazards model. Diabetes mellitus, peripheral arterial disease, peripheral neuropathy, and foot deformities were included for potential confounding. RESULTS: A total of 669 individuals were included: 539 in CKD 3, 540 in CKD 4-5, and 259 in dialysis treatment (individuals could progress from one group to the next). Unadjusted foot ulcer incidence rates per 1000 patients per year were 12 for CKD 3, 47 for CKD 4-5, and 104 for dialysis (P < .001). In multivariate analyses, the hazard ratio for incidence of foot ulceration was 4.0 (95% confidence interval [CI], 2.6-6.3) in CKD 4-5 and 7.6 (95% CI, 4.8-12.1) in dialysis treatment compared with CKD 3. Hazard ratios for incidence of major amputation were 9.5 (95% CI, 2.1-43.0) and 15 (95% CI, 3.3-71.0), respectively. CONCLUSIONS: CKD 4-5 and dialysis treatment are independent risk factors for foot ulceration and major amputation compared with CKD 3. Maximum effort is needed in daily clinical practice to prevent foot ulcers and their devastating consequences in all individuals with CKD 4-5 or dialysis treatment.
OBJECTIVE: The objective of this study was to investigate the risk of chronic kidney disease (CKD) stage 4-5 and dialysis treatment on incidence of foot ulceration and major lower extremity amputation in comparison to CKD stage 3. METHODS: In this retrospective study, all individuals who visited our hospital between 2006 and 2012 because of CKD stages 3 to 5 or dialysis treatment were included. Medical records were reviewed for incidence of foot ulceration and major amputation. The time from CKD 3, CKD 4-5, and dialysis treatment until first foot ulceration and first major lower extremity amputation was calculated and analyzed by Kaplan-Meier curves and multivariate Cox proportional hazards model. Diabetes mellitus, peripheral arterial disease, peripheral neuropathy, and foot deformities were included for potential confounding. RESULTS: A total of 669 individuals were included: 539 in CKD 3, 540 in CKD 4-5, and 259 in dialysis treatment (individuals could progress from one group to the next). Unadjusted foot ulcer incidence rates per 1000 patients per year were 12 for CKD 3, 47 for CKD 4-5, and 104 for dialysis (P < .001). In multivariate analyses, the hazard ratio for incidence of foot ulceration was 4.0 (95% confidence interval [CI], 2.6-6.3) in CKD 4-5 and 7.6 (95% CI, 4.8-12.1) in dialysis treatment compared with CKD 3. Hazard ratios for incidence of major amputation were 9.5 (95% CI, 2.1-43.0) and 15 (95% CI, 3.3-71.0), respectively. CONCLUSIONS: CKD 4-5 and dialysis treatment are independent risk factors for foot ulceration and major amputation compared with CKD 3. Maximum effort is needed in daily clinical practice to prevent foot ulcers and their devastating consequences in all individuals with CKD 4-5 or dialysis treatment.
Authors: Douglas Franz; Yuanchao Zheng; Nicholas J Leeper; Venita Chandra; Maria Montez-Rath; Tara I Chang Journal: JAMA Intern Med Date: 2018-08-01 Impact factor: 21.873
Authors: Andrew J Miller; Edwin A Takahashi; William S Harmsen; Kristin C Mara; Sanjay Misra Journal: J Vasc Interv Radiol Date: 2017-09-19 Impact factor: 3.464
Authors: Michelle R Kaminski; Anita Raspovic; Lawrence P McMahon; Bircan Erbas; Karl B Landorf Journal: J Foot Ankle Res Date: 2015-09-18 Impact factor: 2.303
Authors: Michelle R Kaminski; Anita Raspovic; Lawrence P McMahon; Katrina A Lambert; Bircan Erbas; Peter F Mount; Peter G Kerr; Karl B Landorf Journal: BMC Nephrol Date: 2017-09-08 Impact factor: 2.388
Authors: Se-Young Kim; Tae Hoon Kim; Jun-Young Choi; Yu-Jin Kwon; Dong Hui Choi; Ki Chun Kim; Min Ji Kim; Ho Kyung Hwang; Kyung-Bok Lee Journal: Vasc Specialist Int Date: 2018-12-31